PCSK9阻害剤とイノベーション,効率性,手頃な価格の選択
Daniel B Mark1, Kevin A Schulman1
1Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
No abstract available in PubMed .
さらに関連する動画
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
関連する概念動画
Pharmacogenomics: Identification of New Drug Targets
Drug Products: Biologics, Biosimilars and Interchangeables
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Bioequivalence of Drugs: Drugs with Multiple Indications
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Site-Targeted Drug Delivery Systems: Polymeric Carriers
